Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cytovance, Precision Biologics Expand Mfg. Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Cytovance, Precision Biologics Expand Mfg. Pact

To provide additional cGMP manufacturing services to support Phase II trials of NEO-102

Cytovance Biologics, Inc. is extending its manufacturing agreement with Precision Biologics, Inc. for additional cGMP manufacturing services to support ongoing Phase II trials of NEO-102, a therapeutic drug candidate for pancreatic and colorectal cancers. Precision had previously contracted Cytovance as its CMO to provide technology transfer and cGMP manufacturing services.

“With this agreement, Precision Biologics is strengthening its longstanding and growing relationship with the scientific professionals of Cytovance,” said Dr. Albine Martin, chief operating officer of Precision Biologics, Inc. “Cytovance has been a valuable partner in helping us reach another milestone in our program directed towards the treatment of pancreatic and colorectal cancers.”

“Our state-of-the-art facilities and experienced staff are prepared to continue the delivery of clinical materials for Precision Biologics,” said Darren Head, president and chief executive officer of Cytovance Biologics, Inc. “We are proud to be an established partner with Precision Biologics and support them in their expanded clinical trial program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters